• Publications
  • Influence
Heart Disease and Stroke Statistics—2015 Update: A Report From the American Heart Association
Author(s): Mozaffarian, Dariush; Benjamin, Emelia J; Go, Alan S; Arnett, Donna K; Blaha, Michael J; Cushman, Mary; de Ferranti, Sarah; Despres, Jean-Pierre; Fullerton, Heather J; Howard, Virginia J;Expand
  • 5,392
  • 339
  • PDF
Heart disease and stroke statistics--2013 update: a report from the American Heart Association.
Author(s): Go, Alan S; Mozaffarian, Dariush; Roger, Veronique L; Benjamin, Emelia J; Berry, Jarett D; Borden, William B; Bravata, Dawn M; Dai, Shifan; Ford, Earl S; Fox, Caroline S; Franco, Sheila;Expand
  • 5,092
  • 314
Heart Disease and Stroke Statistics—2016 Update: A Report From the American Heart Association
Author(s): Writing Group Members; Mozaffarian, Dariush; Benjamin, Emelia J; Go, Alan S; Arnett, Donna K; Blaha, Michael J; Cushman, Mary; Das, Sandeep R; de Ferranti, Sarah; Despres, Jean-Pierre;Expand
  • 4,891
  • 293
Executive Summary: Heart Disease and Stroke Statistics—2016 Update A Report From the American Heart Association
Author(s): Writing Group Members; Mozaffarian, Dariush; Benjamin, Emelia J; Go, Alan S; Arnett, Donna K; Blaha, Michael J; Cushman, Mary; Das, Sandeep R; de Ferranti, Sarah; Despres, Jean-Pierre;Expand
  • 1,576
  • 98
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
BACKGROUND The cardiovascular safety and efficacy of many current antihyperglycemic agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear. METHODS We randomlyExpand
  • 2,501
  • 94
  • PDF
Executive summary: heart disease and stroke statistics--2013 update: a report from the American Heart Association.
Author(s): Go, Alan S; Mozaffarian, Dariush; Roger, Veronique L; Benjamin, Emelia J; Berry, Jarett D; Borden, William B; Bravata, Dawn M; Dai, Shifan; Ford, Earl S; Fox, Caroline S; Franco, Sheila;Expand
  • 1,695
  • 73
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
BACKGROUND Data are lacking on the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes andExpand
  • 1,317
  • 71
  • PDF
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
BACKGROUND The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium–glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined. METHODSExpand
  • 736
  • 71
  • PDF
Executive summary: heart disease and stroke statistics--2014 update: a report from the American Heart Association.
Author(s): Go, Alan S; Mozaffarian, Dariush; Roger, Veronique L; Benjamin, Emelia J; Berry, Jarett D; Blaha, Michael J; Dai, Shifan; Ford, Earl S; Fox, Caroline S; Franco, Sheila; Fullerton, HeatherExpand
  • 1,249
  • 57
  • PDF
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
BACKGROUND The magnitude of effect of sodium-glucose cotransporter-2 inhibitors (SGLT2i) on specific cardiovascular and renal outcomes and whether heterogeneity is based on key baselineExpand
  • 772
  • 50
  • PDF